Disease · MONDO_0007576
esophageal cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. esophageal cancer. Diseases, record MONDO_0007576. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007576
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cancer of esophagus, cancer of oesophagus, esophageal cancer, somatic, esophageal carcinoma, somatic, esophageal squamous cell carcinoma, somatic, esophagus cancer, malignant esophageal neoplasm, malignant esophageal tumor, malignant esophageal tumour, malignant esophagus neoplasm, malignant esophagus tumor, malignant neoplasm of esophagus, malignant neoplasm of oesophagus, malignant neoplasm of the esophagus, malignant neoplasm of the oesophagus, malignant oesophagus neoplasm, malignant oesophagus tumour, malignant tumor of esophagus, malignant tumor of the esophagus, malignant tumour of oesophagus, malignant tumour of the oesophagus, oesophagus cancer
- Open Targets
Drugs156
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TISLELIZUMAB | CHEMBL4297840 | Antibody | Approval | PMDA | 7 | 6 | 6 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 95 | 95 | 95 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 77 | 77 | 74 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 67 | 67 | 64 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 3 | ClinicalTrials.gov | 44 | 44 | 40 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 37 | 37 | 36 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 35 | 35 | 34 | Drugs and targets |
| IRINOTECAN | CHEMBL481 | Small molecule | Phase 3 | ClinicalTrials.gov | 23 | 23 | 22 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 3 | ClinicalTrials.gov | 21 | 21 | 20 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 3 | TTD | 21 | 20 | 20 | Drugs and targets |
1 to 10 of 156
See all 156 drugsTargets176
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 15 | Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 11 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 11 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Approval | https://conductscience.org/library/genes/5133 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 8 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| ERBB2 | Epidermal growth factor receptor | 7 | Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 3 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 7 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 6 | Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| TYMS | Thymidylate synthase | 6 | Thymidylate synthase inhibitor | Phase 3 | https://conductscience.org/library/genes/7298 | Drugs and targets |
| ERBB4 | Epidermal growth factor receptor | 5 | Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | Phase 2 | https://conductscience.org/library/genes/2066 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 5 | Stem cell growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
1 to 10 of 176
See all 176 targetsTrials327
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02743494 | An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer | Phase 3 | 794 | 2021-06-22 | Advanced Cancer | NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | Phase 1/2 | 515 | 2021-04-06 | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer | SACITUZUMAB GOVITECAN | Its record names the disease | ClinicalTrials.gov |
| NCT02569242 | Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer | Phase 3 | 419 | 2022-01-14 | Esophageal Cancer | DOCETAXEL, NIVOLUMAB, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00655876 | Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer | Phase 3 | 344 | 2018-03-14 | Esophageal Cancer | CETUXIMAB, CISPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT01333033 | PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy | Phase 2 | 257 | 2021-11-03 | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | CARBOPLATIN, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00381706 | Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | Phase 2 | 245 | 2017-03-15 | Esophageal Cancer | CETUXIMAB, CISPLATIN, EPIRUBICIN, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT01498289 | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | Phase 2 | 213 | 2019-08-29 | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer | DOCETAXEL, FLUOROURACIL, IRINOTECAN HYDROCHLORIDE, LEUCOVORIN CALCIUM, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT01196390 | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | Phase 3 | 203 | 2021-05-04 | Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7 | TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01362127 | Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia | Phase 2 | 181 | 2020-02-26 | Carcinoma, Squamous Cell, Adenocarcinoma of the Esophagus and Gastric Cardia | CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT03433898 | This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer | Early phase 1 | 146 | 2025-12-19 | Neoplasms | EZABENLIMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 327
See all 327 trialsComparisons in its trials46
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nivolumab vs Placebo: deaths from any cause | 299 of 532 | 162 of 262 | 794 | NCT02743494 | Trial comparisons |
| Nivolumab vs Placebo: serious adverse events | 196 of 532 | 99 of 260 | 792 | NCT02743494 | Trial comparisons |
| Nivolumab Arm vs Active Comparator Arm （Docetaxel/Paclitaxel）: deaths from any cause | 7 of 209 | 5 of 208 | 417 | NCT02569242 | Trial comparisons |
| Nivolumab Arm vs Active Comparator Arm （Docetaxel/Paclitaxel）: serious adverse events | 68 of 209 | 77 of 208 | 417 | NCT02569242 | Trial comparisons |
| Chemoradiation + Cetuximab vs Chemoradiation: serious adverse events | 88 of 162 | 88 of 173 | 335 | NCT00655876 | Trial comparisons |
| Arm I FOLFOX vs Arm II IT: deaths from any cause | 89 of 98 | 94 of 104 | 202 | NCT01498289 | Trial comparisons |
| Chemoradiation and Trastuzumab (Arm 1) vs Chemoradiation (Arm 2): Number of Participants With Any Cardiac Adverse Events Regardless of Attribution | 30 of 95 | 24 of 96 | 191 | NCT01196390 | Trial comparisons |
| Chemoradiation and Trastuzumab vs Chemoradiation: deaths from any cause | 53 of 95 | 55 of 96 | 191 | NCT01196390 | Trial comparisons |
| Chemoradiation and Trastuzumab vs Chemoradiation: serious adverse events | 51 of 95 | 34 of 96 | 191 | NCT01196390 | Trial comparisons |
| Arm I FOLFOX vs Arm II IT: serious adverse events | 7 of 91 | 17 of 98 | 189 | NCT01498289 | Trial comparisons |
1 to 10 of 46
See all 46 comparisons in its trialsPapers from its trials181
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007576
GET https://conductscience.org/api/diseases/v1/MONDO_0007576/drugs?page=2